Bone Loss Prevention of Bisphosphonates in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

Table 2

Summary of the number of adverse events, nonvertebral and vertebral fractures between the bisphosphonate and control groups.

Trial	Year	Bisphosphonate group				Control group
		Number of patients	Number of adverse events	Number of nonvertebral fractures	Number of vertebral fractures	Number of patients	Number of adverse events	Number of nonvertebral fractures	Number of vertebral fractures
Bartram et al.	2003	37	4			37	3
Haderslev et al.	2000	15	12	0	1	17	13	1	2
Siffledeen et al.	2005	71	5		1	72	2		0
Soo et al.	2012	45	2			43	3
Tirpitz et al.	2003	35	9			13	3
Klaus et al.	2011	54	12		0	32	9		1
Henderson et al.	2006	30	18	1		31	19	1
Palomba et al.	2005	45	5	0	5	45	2	4	14
van Bodegraven et al.	2014	64	0		0	67	1		1
Abitbol et al.	2007	33	26			34	24
Kitazaki et al.	2009	19	3			20	1